Pfiz­er brings Ibrance to new sub­set of breast can­cer pa­tients, re­gard­less of menopausal sta­tus

Pfiz­er has ex­pand­ed Ibrance’s use to in­clude a new sub­set of breast can­cer pa­tients, the com­pa­ny slipped in­to its quar­ter­ly earn­ings re­port on Tues­day.

The drug was ap­proved in com­bi­na­tion with an aro­matase in­hibitor (AI) in mid-De­cem­ber to treat women with HR-pos­i­tive, HER2-neg­a­tive metasta­t­ic breast can­cer re­gard­less of menopausal sta­tus, Pfiz­er an­nounced.

Ibrance was first ap­proved in post­menopausal women with ad­vanced breast can­cer back in 2015. The CDK4/6 in­hibitor has since racked up a slate of la­bel ex­pan­sions, but un­til the lat­est add-on, the AI com­bo treat­ment was on­ly in­di­cat­ed for post­menopausal women or men.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.